v3.24.3
Out-Licensing Agreements (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
item
Feb. 28, 2022
USD ($)
item
agreement
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Collaborative agreements                    
Revenue     $ 112,214     $ 67,046 $ 300,703 $ 186,864    
License and collaboration revenue                    
Collaborative agreements                    
Revenue           2,244 6,210 24,908    
Collaboration Agreements                    
Collaborative agreements                    
Upfront payments received   $ 22,000                
Number of agreements entered into | agreement   2                
Term of agreement for royalty payments   12 years                
Territory License - Rilonacept                    
Collaborative agreements                    
Upfront payments received   $ 12,000 12,000              
Transaction price   $ 12,000                
Number of performance obligations in an agreement | item   1                
Payments to be received by the company upon the achievement of specified development, regulatory and sales milestones   $ 70,000                
Territory License - Rilonacept | Non-current deferred revenue                    
Collaborative agreements                    
Transaction price             11,811      
Territory License - Rilonacept | License and collaboration revenue                    
Collaborative agreements                    
Revenue     0     0 189 0    
Territory License - Mavrilimumab                    
Collaborative agreements                    
Upfront payments received   10,000                
Transaction price   10,000                
Payments to be received by the company upon the achievement of specified development, regulatory and sales milestones   $ 576,000                
Territory License - Mavrilimumab | License and collaboration revenue                    
Collaborative agreements                    
Revenue                   $ 10,000
Worldwide License - Vixarelimab                    
Collaborative agreements                    
Upfront payments received $ 80,000                  
Payments received upon delivery of certain materials                 $ 20,000  
Milestone receipts       $ 5,000         15,000  
Transaction price $ 80,000                  
Addition to transaction price         $ 10,000   5,000   $ 25,000 $ 20,000
Number of performance obligations in an agreement | item 4                  
Payments to be received by the company upon the achievement of specified development, regulatory and sales milestones             570,000      
Worldwide License - Vixarelimab | Maximum                    
Collaborative agreements                    
Payments to be received by the company upon the achievement of specified development, regulatory and sales milestones $ 600,000                  
Worldwide License - Vixarelimab | License and collaboration revenue                    
Collaborative agreements                    
Revenue     $ 0     $ 2,244 5,261 $ 24,908    
Revenue recognized related to performance obligations satisfied in prior periods             $ 4,989